Lgenia
- Company typePrivate
- Founded2017
- HeadquartersFortville, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Lgenia firmographics
Firmographics- Name
- Lgenia
- Legal name
- Lgenia, Inc.
- Website
- https://lgenia.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Lgenia industry classification
Industry- Product category
- Drug Discovery / Pharmaceutical R&D Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
- akta.pro secondary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Lgenia is headquartered
LocationHeadquarters
- HQ city
- Fortville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Lgenia business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Grant and Foundation Funding: Lgenia operates as a pre-revenue research-stage biotechnology company funded primarily through grants, foundation funding, and government research contracts. The company does not have commercial products yet and focuses on drug discovery research partnerships.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
Lgenia product offering
Product offeringCore offering
Lgenia is a research-stage biotechnology company that discovers and develops small-molecule therapeutics for tuberculosis, malaria, Alzheimer's disease, and non-hormonal contraceptives in women's health. It conducts drug discovery through collaborative partnerships with academic institutions, pharmaceutical companies, and global health foundations, leveraging computational chemistry and AI-enabled platforms. The company does not yet sell commercial products, instead delivering its work via grant-funded research collaborations and consortium-based open innovation programs.
Product overview
Lgenia is a biotechnology company that operates as a unified drug discovery platform focused on four therapeutic areas: Tuberculosis, Malaria, Alzheimer's Disease, and Women's Health (specifically non-hormonal contraceptives). The company does not offer a modular software platform but rather provides drug discovery services and expertise, leveraging collaborative partnerships with academic institutions, pharmaceutical companies, and research organizations. Lgenia's research portfolio includes a SHIP1 inhibitor program for Alzheimer's disease as its most advanced clinical-stage target, along with various compound discovery efforts across TB, malaria, and reproductive health.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug Discovery Program for Tuberculosis Discovery and development of new medications for tuberculosis, including work on drug-resistant strains and novel mechanisms of action to shorten treatment duration and improve patient compliance.
- Drug Discovery Program for Malaria Development of innovative antimalarial compounds targeting resistant parasites and preventing transmission, including single-dose treatment concepts and next-generation antimalarials.
- Drug Discovery Program for Alzheimer's Disease Pioneering neuro-immune targets to slow cognitive decline and preserve quality of life, focusing on early intervention strategies and novel therapeutic approaches for Alzheimer's disease.
- Non-Hormonal Contraceptive Discovery Program Discovery program advancing non-hormonal contraceptives to expand reproductive health options and access for women.
- SHIP1 Inhibitor Program Lgenia's most advanced therapeutic target for Alzheimer's disease, targeting SHIP1 (encoded by INPP5D), a microglia-specific gene associated with late-onset Alzheimer's disease, with funding to advance into clinical trials.
Quantifiable outcome
- 8.3 million new TB cases and ~1.23 million deaths in 2024 addressed through drug discovery efforts
- +2 more outcomes
Companies that use Lgenia
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Lgenia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Lgenia partnerships and signals
Strategic signalPartnerships
30 partnerships are on record, tiered major, core and minor.
- ChemifymajorAI-powered drug discovery collaboration using Chemputation platform for tuberculosis drug design and synthesis. Gates Foundation awarded £1.2M additional funding (total £2.4M project funding) for this collaboration.
- Indiana University School of MedicinecoreTREAT-AD Center partnership for Alzheimer's disease drug discovery, focusing on neuro-immune targets including SHIP1. IU received $36M initial NIH grant and $41.6M five-year renewal for the center.
- TB AlliancemajorGlobal partnership dedicated to accelerating discovery and development of new tuberculosis treatments through the TB Drug Accelerator consortium.
- Medicines for Malaria Venture (MMV)majorPartnership for antimalarial drug discovery, contributing to Malaria Drug Accelerator program and next-generation malaria treatments.
- AbbViemajorPharmaceutical industry partner in drug discovery collaborations, contributing expertise and resources to TB Drug Accelerator and other programs.
- GSKmajorPharmaceutical partner in TB Drug Accelerator consortium, bringing global drug development expertise and screening capabilities.
- Janssen (Johnson & Johnson)majorPharmaceutical industry collaboration in TB Drug Accelerator, contributing to open innovation drug discovery efforts.
- Broad InstitutemajorResearch institute partnership providing genomics and computational biology capabilities for drug discovery programs.
- Calibr at Scripps ResearchmajorResearch institute partnership contributing to drug discovery research and translational science capabilities.
- Harvard T.H. Chan School of Public HealthmajorAcademic partner joining TB Drug Accelerator in 2018 alongside Lgenia, bringing public health and epidemiology expertise.
- University of Dundee (Drug Discovery Unit)majorAcademic partnership for drug discovery, particularly in neglected tropical diseases, with active collaboration in Ghana mentorship program.
- EvotecmajorBiotechnology partner providing drug discovery platforms and expertise through various collaboration arrangements.
- Purdue UniversitymajorTREAT-AD Center partner contributing computational chemistry and drug discovery expertise for Alzheimer's research.
- University of PittsburghmajorTREAT-AD Center partner contributing neuroscience and neurobiology expertise to Alzheimer's disease research collaboration.
- University of GhanaminorGates Foundation-funded Drug Innovations Group (DIG) partnership with chemistry department, mentored by Lgenia for neglected disease drug discovery.
- Noguchi Memorial Institute for Medical Research (NMIMR)minorBiology research facility within University of Ghana conducting biological testing for neglected disease drug discovery programs.
- Kwame Nkrumah University of Science and Technology (KNUST)minorGhanaian university partner conducting pharmacokinetic studies as part of collaborative drug discovery program mentored by Lgenia.
- Global Health Drug Discovery Institute (GHDDI)minorGlobal health drug discovery institute partnership contributing to neglected disease research capabilities.
- UC San DiegominorAcademic research partnership in drug discovery, contributing scientific expertise to various collaboration programs.
- Texas A&M UniversityminorAcademic partnership contributing research capabilities to drug discovery initiatives.
- MITminorAcademic partnership bringing advanced research capabilities to collaborative drug discovery programs.
- Washington University in St. LouisminorAcademic partnership contributing to Alzheimer's disease research and drug discovery expertise.
- Columbia UniversityminorAcademic research partnership contributing neuroscience and biomedical research capabilities.
- Weill Cornell MedicineminorAcademic medical partnership contributing biomedical research and drug discovery expertise.
- Wellcome Sanger InstituteminorGenomics research institute partnership contributing to target identification and validation capabilities.
- Seattle Children's Research InstituteminorPediatric research institute partnership contributing to global health and infectious disease research.
- Indiana Biosciences Research Institute (IBRI)minorResearch institute partner in TREAT-AD center, providing state-of-the-art laboratory facilities and research capabilities.
- EisaiminorPharmaceutical partner in drug discovery collaborations, contributing to Alzheimer's disease research efforts.
- MerckminorPharmaceutical industry partner contributing to drug discovery research programs.
- TROPIQ Health SciencesminorSpecialized health sciences research institute partnership contributing to infectious disease drug discovery.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Lgenia competitors and assessment
Company assessmentDirect peers
- TB Alliance: Global non-profit product development partnership dedicated to discovering and developing affordable tuberculosis treatments. Directly comparable to Lgenia's TB drug discovery focus and a current Lgenia partner within the TB Drug Accelerator consortium.
- An2 Therapeutics: Clinical-stage biopharmaceutical company developing novel treatments for infectious diseases including drug-resistant tuberculosis. Comparable to Lgenia as a small, focused TB drug discovery company advancing assets into clinical development.
- Drugs for Neglected Diseases initiative: Non-profit R&D organization developing new treatments for neglected diseases including tuberculosis, malaria, and other infectious diseases affecting low-income populations. Comparable as a grant-funded, mission-aligned drug discovery organization operating across the same disease areas.
- BioVersys: Swiss clinical-stage pharmaceutical company developing small-molecule therapeutics for antimicrobial resistance, with tuberculosis as a core focus. Comparable to Lgenia as a smaller, focused anti-infective drug discovery company working on drug-resistant TB.
- Medicines for Malaria Venture: Product development partnership working to discover, develop, and deliver new antimalarial drugs. Directly comparable to Lgenia's malaria drug discovery program and a current Lgenia partner within the Malaria Drug Accelerator.
Broad incumbents
- Karuna Therapeutics: Neuroscience-focused biopharmaceutical company developing therapies for CNS disorders including Alzheimer's-related cognitive symptoms. Comparable to Lgenia's Alzheimer's program as a larger, neuroscience-focused CNS drug discovery company.
- Calibr at Scripps Research: Drug discovery and translational science division of Scripps Research working on first-in-class therapeutics across multiple disease areas. Comparable to Lgenia as a current TB Drug Accelerator partner with broader drug discovery capabilities.
- Evotec: Large drug discovery and development services company providing end-to-end R&D platforms and partnerships across multiple therapeutic areas including infectious diseases and neuroscience. Comparable to Lgenia as a current partner, with broader drug discovery service capabilities.
- Biogen: Major biopharmaceutical company with one of the largest Alzheimer's disease drug development pipelines including FDA-approved treatments. Comparable to Lgenia as a broad incumbent in Alzheimer's drug discovery and a current Lgenia partner ecosystem participant.
Emerging players
- Cerevel Therapeutics: Clinical-stage neuroscience company developing targeted therapies for CNS disorders including Alzheimer's disease and other neurodegenerative conditions. Comparable to Lgenia's Alzheimer's program as a smaller, neuroscience-focused biotech pursuing novel CNS mechanisms.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Lgenia social profiles
Digital presenceLgenia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lgenia leadership team
Management profileNumber of profiles
Profiles9 records
Lgenia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lgenia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lgenia
What does Lgenia do?
Lgenia is a research-stage biotechnology company that discovers and develops small-molecule therapeutics for tuberculosis, malaria, Alzheimer's disease, and non-hormonal contraceptives in women's health. It conducts drug discovery through collaborative partnerships with academic institutions, pharmaceutical companies, and global health foundations, leveraging computational chemistry and AI-enabled platforms. The company does not yet sell commercial products, instead delivering its work via grant-funded research collaborations and consortium-based open innovation programs.
Is Lgenia a public or private company?
Lgenia is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Lgenia founded?
Lgenia was founded in 2017. It employs 11 to 50 people.
Where is Lgenia based?
Lgenia is headquartered in Fortville, United States, in the North America region.
How does Lgenia make money?
One revenue line is on record: grant and Foundation Funding.
Who are Lgenia's main competitors?
Direct peers on record are TB Alliance, An2 Therapeutics, Drugs for Neglected Diseases initiative, BioVersys and Medicines for Malaria Venture. Broad incumbents are Karuna Therapeutics, Calibr at Scripps Research, Evotec and Biogen. Cerevel Therapeutics is listed as an emerging player.
Does Lgenia have an API?
No public API is recorded for Lgenia.
What industry is Lgenia in?
Lgenia's product category is Drug Discovery / Pharmaceutical R&D Services. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.